Celgene (CELG) Upgraded at Vetr

Celgene (NASDAQ:CELG) was upgraded by investment analysts at Vetr from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday. The brokerage presently has a $114.80 price target on the biopharmaceutical company’s stock. Vetr‘s price objective suggests a potential upside of 12.53% from the stock’s previous close.

CELG has been the topic of a number of other reports. BMO Capital Markets increased their price objective on shares of Celgene from $148.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, November 17th. Cantor Fitzgerald set a $112.00 price objective on shares of Celgene and gave the stock a “hold” rating in a research report on Wednesday. Oppenheimer reissued a “buy” rating and issued a $170.00 price objective on shares of Celgene in a research report on Friday, October 20th. Cann reissued a “buy” rating on shares of Celgene in a research report on Thursday, October 26th. Finally, Morgan Stanley raised shares of Celgene from an “underweight” rating to an “equal weight” rating in a research report on Friday, October 27th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $130.95.

Shares of Celgene (NASDAQ:CELG) traded down $2.80 during midday trading on Wednesday, hitting $102.02. 11,870,000 shares of the stock traded hands, compared to its average volume of 6,290,000. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The stock has a market cap of $80,320.00, a PE ratio of 24.06, a price-to-earnings-growth ratio of 0.68 and a beta of 1.77. Celgene has a 52-week low of $94.55 and a 52-week high of $147.17.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to analysts’ expectations of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS. equities analysts forecast that Celgene will post 6.69 EPS for the current fiscal year.

A number of hedge funds have recently modified their holdings of CELG. Cullinan Associates Inc. boosted its stake in shares of Celgene by 1.8% during the fourth quarter. Cullinan Associates Inc. now owns 63,375 shares of the biopharmaceutical company’s stock valued at $6,614,000 after purchasing an additional 1,107 shares in the last quarter. Charter Trust Co. boosted its stake in shares of Celgene by 108.3% during the fourth quarter. Charter Trust Co. now owns 8,668 shares of the biopharmaceutical company’s stock valued at $904,000 after purchasing an additional 4,507 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its stake in shares of Celgene by 2.8% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 3,228,643 shares of the biopharmaceutical company’s stock valued at $336,917,000 after purchasing an additional 87,533 shares in the last quarter. Burns J W & Co. Inc. NY boosted its stake in shares of Celgene by 7.4% during the fourth quarter. Burns J W & Co. Inc. NY now owns 47,748 shares of the biopharmaceutical company’s stock valued at $4,983,000 after purchasing an additional 3,275 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its stake in shares of Celgene by 10.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 6,249 shares of the biopharmaceutical company’s stock valued at $652,000 after purchasing an additional 569 shares in the last quarter. Institutional investors and hedge funds own 79.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Celgene (CELG) Upgraded at Vetr” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3143316/celgene-celg-upgraded-at-vetr.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.